The global Cancer Monoclonal Antibodies market size was estimated at USD 62.4 billion in 2021 and is expected to surpass around USD 160.7 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 11.9% during the forecast period 2022 to 2030.
Key Takeaways:
Monoclonal antibody-based immunotherapy is a major element of cancer therapy besides surgery, chemotherapy, and radiation. mAbs have been recognized as one of the utmost successful therapeutic approaches for both solid tumors and hematologic malignancies in the last 20 years. The rising prevalence of cancer and increasing drug approvals along with a robust pipeline are the key factors augmenting the market growth. Millions of people globally stand to benefit both from the current monoclonal antibody-based therapies and those that are in development.
Moreover, mAbs have reduced side effects on the patient’s body when compared to chemotherapy. Furthermore, the growing adoption of cost-efficient biosimilar mAbs by oncologists and medical practitioners will further provide a boost to the growth of the market during the forecast period. In March 2020, the WHO designated COVID-19 as a pandemic. This outbreak has considerably affected both the world and the U.S. markets. In response to the COVID-19 outbreak, governments of many cities, counties, states, and other geographic regions have taken protective or preventative actions, such as imposing restrictions. As COVID-19 reached a tipping point in the U.S. and Europe during the last two weeks of March 2020, its far-reaching consequences were observed across industries and businesses, with hospitals postponing or canceling treatment procedures for cancer and halting clinical trials.
Moreover, the reduced access to health care systems to contain the pandemic resulted in a sharp decline in cancer screening. For instance, breast cancer screening saw an 87% decline in April 2020 compared to the average for the same month over the last five years. Many cancer patients had to delay or postpone their cancer treatment, which led to concerns about timely access to cancer treatments and disease recurrence or cancellation of cancer treatments. Cancer is a class of chronic diseases categorized by uncontrolled cell growth. The increasing number of cancer cases is anticipated to increase the demand for monoclonal antibodies and propel market growth.
According to the American Society of Clinical Oncology, by the end of 2022, there will be a projected 1.9 million diagnosed cancer cases and 609,360 deaths in the U.S. In addition, estimates by the same source projected that in 2020, an estimated 176,000 people globally were diagnosed with multiple myeloma. In 2022, it is projected that more than 34,000 individuals will be diagnosed with multiple myeloma, and above 12,000 people will die in the U.S. Over the past couple of years, the US FDA has approved more than a dozen monoclonal antibodies for treating various types of cancer. As scientists have discovered more antigens connected to cancer, they have been able to develop monoclonal antibodies against several cancer types.
In addition, clinical trials of newer monoclonal antibodies are now being carried out for various types of cancer. mAbs present a huge opportunity for the treatment of cancer due to their specificity. Their use will witness increasing demand during the forecast period, as science determines more and more novel targets in cancer cells. Many types of tumors are presently being treated with these novel biological drugs. Treatment standards involving monoclonal antibodies will continue to progress and have the probability to offer therapeutic options for cancer patients in the coming years.
Report Scope of the Cancer Monoclonal Antibodies Market
Report Coverage |
Details |
Market Size |
US$ 160.7 Billion by 2030 |
Growth Rate |
CAGR of 11.9% from 2022 to 2030 |
Largest Market |
North America |
Fastest Growing Market |
Asia Pacific |
Base Year |
2021 |
Forecast Period |
2022 to 2030 |
Segments Covered |
Type, application, end-user, and Region, |
Companies Mentioned |
F. Hoffmann-La Roche Ltd.; Bristol Myers Squibb Co.; Merck & Co.; GlaxoSmithKline plc; Johnson & Johnson; Amgen, Inc.; Novartis AG; AstraZeneca plc; Eli Lilly and Company; AbbVie |
Type Insights
The humanized segment held the highest market share of 39.7% in 2021. Humanized monoclonal antibodies are engineered to replace the mouse-related immunogenic or epitope structures. Due to the low cost, availability, and quick production time for mouse monoclonal antibodies, the humanization of mouse monoclonal antibodies has been applied on a large scale, thereby driving the growth of the market. In addition, 50% of newly approved mAbs are humanized monoclonal antibodies.
Furthermore, innovative genetic engineering technology engaged in its production is another potential growth driver for this segment. Several humanized antibodies have now been constructed and designed, and many are at present being evaluated in clinical trials. However, the human segment is expected to be the fastest growing during the forecast period. An increase in the number of product approvals and product launches of human mAbs will positively impact the growth of the segment during the assessment years.
Application Insights
The blood cancer segment held the highest market share of 23.6% in 2021. There has been a tremendous increase in demand for hematological disorder treatments over the last three years, which has led pharmaceutical industries to develop novel medications, including cancer monoclonal antibodies. For instance, in August 2020, the FDA approved GSK’s BLENREP for treating patients with refractory or relapsed multiple myeloma.
However, lung cancer is expected to be the fastest-growing segment during the forecast period with the highest CAGR. The increasing prevalence of lung cancer will drive the product demand in near future. NSCLC is the most common type of lung cancer, and it accounts for about 85% of all lung cancer cases, with more than 2 million new cases in 2020 globally. Moreover, to cater growing burden of the disease, significant market players are implementing developmental activities that will offer growth opportunities in the near future. For instance, in June 2022, FDA accepted the application for Merck’s KEYTRUDA as an Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer after the completion of surgical resection.
End-user Insights
The hospitals segment held the highest revenue share of 39.9% in 2021. Some of the factors that can be attributed to the segmental share include the rising prevalence of cancer along with an upsurge in the number of patient hospitalizations. In addition, the availability of innovative drug therapies in hospitals drives patient preference. Furthermore, skilled professionals offering specialty treatments will drive the product demand in the hospitals.
Additionally, strategic activities by research organizations are going to generate lucrative growth opportunities during the review period. For instance, IRBM signed an agreement with The University of Texas MD Anderson Cancer Center in 2019. The contract focuses on the development of therapeutic mAbs against novel immune checkpoint targets. Similarly, in 2021, Celltrion Healthcare signed an agreement with the Brazilian Ministry of Health to supply two of its anticancer therapeutics - Truxima and Herzuma - to the market.
Regional Insights
North America dominated the cancer monoclonal antibodies market with a share of 37.8% in 2021. Strategic activities are key factors influencing the market growth. For instance, in September 2020, AbbVie and I-Mab signed a broad, international partnership agreement for the commercialization and development of lemzoparlimab, an advanced anti-CD47 monoclonal antibody discovered and developed by I-Mab for multiple cancers treatment. The partnership also allows for future collaboration on CD47-associated therapeutic agents.
Asia Pacific is estimated to be the fastest-growing region owing to increasing efforts by global firms to penetrate this emerging market to capture a higher share. An increasing number of international and national collaborations among entities, especially those in developed and developing countries, is expected to propel the market. In addition, an increase in the adoption of biosimilars in the region will further offer lucrative opportunities in the review period. For instance, in recent years, China’s biosimilar drug industry has established rapidly. By the end of 2019, the country had the maximum number of biosimilar drugs in research, with 391 biosimilar drugs in the research and development pipeline. As of December 2020, 11 biosimilar drugs had been accepted for marketing in China, comprising 6 drugs for oncology
Some of the prominent players in the Cancer Monoclonal Antibodies Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Cancer Monoclonal Antibodies market
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Points Covered in Cancer Monoclonal Antibodies Market Study:
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cancer Monoclonal Antibodies Market
5.1. COVID-19 Landscape: Cancer Monoclonal Antibodies Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cancer Monoclonal Antibodies Market, By Type
8.1. Cancer Monoclonal Antibodies Market, by Type, 2022-2030
8.1.1 Humanized
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Human
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Chimeric
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Murine
8.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Cancer Monoclonal Antibodies Market, By Application
9.1. Cancer Monoclonal Antibodies Market, by Application, 2022-2030
9.1.1. Blood Cancer
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Breast Cancer
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Lung Cancer
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Melanoma
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Colorectal Cancer
9.1.5.1. Market Revenue and Forecast (2017-2030)
9.1.6. Liver Cancer
9.1.6.1. Market Revenue and Forecast (2017-2030)
9.1.7. Others
9.1.7.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Cancer Monoclonal Antibodies Market, By End-user
10.1. Cancer Monoclonal Antibodies Market, by End-user, 2022-2030
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Research Institutes
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Cancer Monoclonal Antibodies Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Type (2017-2030)
11.1.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.3. Market Revenue and Forecast, by End-user (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Type (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.5.3. Market Revenue and Forecast, by End-user (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.3. Market Revenue and Forecast, by End-user (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.5.3. Market Revenue and Forecast, by End-user (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.6.3. Market Revenue and Forecast, by End-user (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.7.3. Market Revenue and Forecast, by End-user (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.3. Market Revenue and Forecast, by End-user (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.5.3. Market Revenue and Forecast, by End-user (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.6.3. Market Revenue and Forecast, by End-user (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.7.3. Market Revenue and Forecast, by End-user (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.5.3. Market Revenue and Forecast, by End-user (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.6.3. Market Revenue and Forecast, by End-user (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.7.3. Market Revenue and Forecast, by End-user (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.3. Market Revenue and Forecast, by End-user (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Type (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.5.3. Market Revenue and Forecast, by End-user (2017-2030)
Chapter 12. Company Profiles
12.1. F. Hoffmann-La Roche Ltd.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bristol Myers Squibb Co.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Merck & Co.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. GlaxoSmithKline plc
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Johnson & Johnson
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Amgen, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Novartis AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. AstraZeneca plc
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Eli Lilly and Company
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. AbbVie
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms